baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out LLY/ DE000UM2GB31 /

2024-09-06 7:33:12 PM	Chg.-1.290	Bid9:54:12 PM	Ask9:54:12 PM	Underlying	Strike price	Expiration date	Option type
19.380EUR	-6.24%	- Bid Size: -	- Ask Size: -	Eli Lilly and Co	688.0869 USD	2078-12-31	Call

Newsfile Corp 08-28 The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Wei...

GlobeNewswire 08-27 Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership...

GlobeNewswire 08-26 Eliem Therapeutics Announces Additions to its Leadership Team

GlobeNewswire 08-21 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Co...

GlobeNewswire 08-14 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s ...

GlobeNewswire 08-14 Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD...

GlobeNewswire 08-08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-08 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...

TeleTrader 08-08 US opens higher with data, earnings in focus

GlobeNewswire 08-08 ProQR Announces Second Quarter 2024 Operating and Financial Results

TeleTrader 08-08 Eli Lilly's Q2 revenue jumps 36% to $11.3B

GlobeNewswire 08-08 Defiance Launches LLYX, the First 2X Leveraged Single-Stock ETF on Eli Lilly

GlobeNewswire 08-07 Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire 08-06 Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Rea...

GlobeNewswire 08-06 SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discov...

GlobeNewswire 08-02 Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Cl...

GlobeNewswire 08-01 Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

GlobeNewswire 08-01 COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives

GlobeNewswire 08-01 Compass Pathways announces second quarter 2024 financial results and business highlights

GlobeNewswire 07-31 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFC, HMNF, MORF on Behalf of Shareholders

GlobeNewswire 07-31 MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Hold...

GlobeNewswire 07-31 Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

GlobeNewswire 07-31 HUTCHMED Reports 2024 Interim Results and Provides Business Updates

GlobeNewswire 07-30 Montara Therapeutics Closes $8 Million Seed Round Led by SV Health Investors’ Dementia Discovery Fun...

UBS Knock-Out LLY/ DE000UM2GB31 /

If you wish to receive reply to your feedback, please provide your email address.